Gene expression profile of cytokines produced in biopsies from patients with American cutaneous leishmaniasis

Imagem de Miniatura
Arquivos
art_HIPPOLITO_Gene_expression_profile_of_cytokines_produced_in_biopsies_2019.PDF (441.8 KB)
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE BV
Autores
GOMES, Aparecida Helena Souza
MAIA, Marta Marques
MEIRA-STREJEVITCH, Cristina da Silva
KANAMURA, Cristina Takami
PEREIRA-CHIOCCOLA, Vera Lucia
Citação
ACTA TROPICA, v.189, p.69-75, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
American cutaneous leishmaniasis (ACL) causes a local inflammatory process, inducing expression of several cytokine genes. Particularly, IFN-gamma can predict to disease susceptibility. Based in these data, this study was aimed to investigate the gene expression profile of IFN-gamma, IL-10, IL-27, TNF-gamma, TGF-beta and IL-6 produced in biopsies from ACL patients; and whether the gene expression profile of IFN-gamma could determine the disease evolution. Gene expression of 6 cytokines was investigated in 40 formalin-fixed paraffin embedded (FFPE) biopsies from patients with cutaneous leishmaniosis (CL); and 10 FFPE biopsies from patients with mucosal leishmaniasis (ML) (control). All 50 patients were infected with Leishmania (Viannia) braziliensis. Gene expression was determined by qPCR; and a normal control group was used for calculations (5 normal biopsies). Values were expressed as Relative Quantification (RQ). The 40 CL patients were classified into 2 groups. CLlowIFN-gamma, 35 patients with RQ for IFN-gamma below 100; and CLhighIFN-gamma, 5 (12.5%) patients with RQ above 100. Significant increase of mRNA levels of IFN-gamma, IL-10 and IL-27 was shown in CLhighIFN-gamma group when compared with CLlowIFN-gamma and ML groups. TNF-alpha levels in CLlowIFN-gamma group were higher than CLhighIFN-gamma and ML groups. TGF-beta and IL-6 were similar in 3 groups. Comparison of cytokine expression/group showed that CLlowIFN-gamma group had an equilibrium between the cytokines analyzed. In ML group, IFN-gamma was over-expressed; but in CLhighIFN-gamma group, besides IFN-gamma, IL-27 was also over-expressed. The immune response to Leishmania induces to identification of some markers, which can be determined by analysis by gene expression of cytokines produced in biopsies.
Palavras-chave
American cutaneous leishmaniasis, Leishmania (Viannia) braziliensis, Gene expression, Cytokines, Biopsies
URI
https://observatorio.fm.usp.br/handle/OPI/30305
Referências
  1. Alexander J, 2005, IMMUNOL LETT, V99, P17, DOI 10.1016/j.imlet.2005.01.009
  2. [Anonymous], 2017, NON TRADITIONAL REF
  3. Antonelli LRV, 2005, IMMUNOL LETT, V101, P226, DOI 10.1016/j.imlet.2005.06.004
  4. Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002
  5. Barry MA, 2014, AM J TROP MED HYG, V91, P345, DOI 10.4269/ajtmh.14-0124
  6. Bogdan C, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00069
  7. Cardoso TM, 2015, INFECT IMMUN, V83, P898, DOI 10.1128/IAI.02404-14
  8. Carneiro PP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148084
  9. Carvalho LP, 2007, PARASITE IMMUNOL, V29, P251, DOI 10.1111/j.1365-3024.2007.00940.x
  10. Carvalho LP, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00301
  11. Castellano LR, 2009, HUM IMMUNOL, V70, P383, DOI 10.1016/j.humimm.2009.01.007
  12. Choi BS, 2009, PARASITE IMMUNOL, V31, P199, DOI 10.1111/j.1365-3024.2009.01094.x
  13. Costa-Silva MF, 2014, MOL IMMUNOL, V57, P74, DOI 10.1016/j.molimm.2013.08.008
  14. Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004
  15. Diaz NL, 2006, CLIN EXP DERMATOL, V31, P114, DOI 10.1111/j.1365-2230.2005.01991.x
  16. Eiras Daniel P, 2015, Curr Treat Options Infect Dis, V7, P52
  17. Faria DR, 2005, INFECT IMMUN, V73, P7853, DOI 10.1128/IAI.73.12.7853-7859.2005
  18. Findlay EG, 2010, J IMMUNOL, V185, P2482, DOI 10.4049/jimmunol.0904019
  19. Follador I, 2002, CLIN INFECT DIS, V34, pE54, DOI 10.1086/340261
  20. Frade AF, 2011, INFECT GENET EVOL, V11, P912, DOI 10.1016/j.meegid.2011.02.014
  21. Franca-Costa J, 2015, J INFECT DIS, V211, P426, DOI 10.1093/infdis/jiu455
  22. Gaze ST, 2006, SCAND J IMMUNOL, V63, P70, DOI 10.1111/j.1365-3083.2005.01707.x
  23. Gollob KJ, 2008, INT IMMUNOPHARMACOL, V8, P1338, DOI 10.1016/j.intimp.2008.03.016
  24. Gomes AHS, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12423
  25. Gomes AHS, 2008, EXP PARASITOL, V119, P319, DOI 10.1016/j.exppara.2008.02.014
  26. Gomes AHS, 2007, VET PARASITOL, V144, P234, DOI 10.1016/j.vetpar.2006.10.008
  27. Gonzalez-Lombana C, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003243
  28. GRIMALDI G, 1993, CLIN MICROBIOL REV, V6, P230
  29. Harris E, 1998, J CLIN MICROBIOL, V36, P1989
  30. Hoseini SG, 2012, J RES MED SCI, V17, P513
  31. Jafari-Shakib R, 2009, ACTA TROP, V109, P61, DOI 10.1016/j.actatropica.2008.09.018
  32. Janeway CA, 2001, MICROBES INFECT, V3, P1167, DOI 10.1016/S1286-4579(01)01477-0
  33. Kane MM, 2001, J IMMUNOL, V166, P1141, DOI 10.4049/jimmunol.166.2.1141
  34. Kemp M, 1997, APMIS Suppl, V68, P1
  35. Lanier LL, 2008, NAT IMMUNOL, V9, P495, DOI 10.1038/ni1581
  36. Lessa HA, 2001, AM J TROP MED HYG, V65, P87, DOI 10.4269/ajtmh.2001.65.87
  37. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  38. Mansueto P, 2007, INT J IMMUNOPATH PH, V20, P435, DOI 10.1177/039463200702000302
  39. Meira-Strejevitch CS, 2017, GENE REP, V7, P98, DOI 10.1016/j.genrep.2017.03.002
  40. Lessa Marcus Miranda, 2007, Rev. Bras. Otorrinolaringol., V73, P843, DOI [10.1590/S0034-72992007000600016, 10.1016/S1808-8694(15)31181-2]
  41. Mougneau E, 2011, IMMUNOL REV, V240, P286, DOI 10.1111/j.1600-065X.2010.00983.x
  42. Murray HW, 2005, LANCET, V366, P1561, DOI 10.1016/S0140-6736(05)67629-5
  43. Novais FO, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003504
  44. Oliveira WN, 2014, CYTOKINE, V66, P127, DOI 10.1016/j.cyto.2013.12.016
  45. PAHO, 2017, LEISHM EP REP AM REP
  46. Pflanz S, 2002, IMMUNITY, V16, P779, DOI 10.1016/S1074-7613(02)00324-2
  47. Pompeu MML, 2001, INFECT IMMUN, V69, P7453, DOI 10.1128/IAI.69.12.7453-7460.2001
  48. Ramos-E-Silva M, 2002, CLIN DERMATOL, V20, P122, DOI 10.1016/S0738-081X(01)00251-6
  49. Rodrigues FMD, 2014, ARCH DERMATOL RES, V306, P163, DOI 10.1007/s00403-013-1396-8
  50. Sacks D, 2002, NAT IMMUNOL, V3, P1041, DOI 10.1038/ni1102-1041
  51. Salhi A, 2008, J IMMUNOL, V180, P6139, DOI 10.4049/jimmunol.180.9.6139
  52. Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3
  53. Scott P, 2003, IMMUNOL RES, V27, P489, DOI 10.1385/IR:27:2-3:489
  54. Souza MD, 2013, MICROB PATHOGENESIS, V57, P27, DOI 10.1016/j.micpath.2013.02.004
  55. Takeda A, 2003, J IMMUNOL, V170, P4886, DOI 10.4049/jimmunol.170.10.4886
  56. Tripathi P, 2007, FEMS IMMUNOL MED MIC, V51, P229, DOI 10.1111/j.1574-695X.2007.00311.x
  57. Ulloa L, 2005, TRENDS MOL MED, V11, P56, DOI 10.1016/j.molmed.2004.12.007
  58. Vieira ELM, 2013, PARASITE IMMUNOL, V35, P65, DOI 10.1111/pim.12012
  59. VIETH M, 1994, SCAND J IMMUNOL, V40, P403, DOI 10.1111/j.1365-3083.1994.tb03481.x
  60. WHO (World Health Organization), 2018, LEISHM FACT SHEET
  61. Yoshimura T, 2006, J IMMUNOL, V177, P5377, DOI 10.4049/jimmunol.177.8.5377
  62. Zarnbrano-Villa S, 2002, TRENDS PARASITOL, V18, P272, DOI 10.1016/S1471-4922(02)02289-4

Coleções
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - LIM/38